Patricia LoRusso, DO, Professor of Medicine (Medical Oncology) and Associate Director of Innovative Medicine at Yale Cancer Center, has been named Chair of the Women in Cancer Research (WICR) Council of the American Association for Cancer Research (AACR). WICR is a membership group within the AACR ...
Allison Aggon, DO, has joined the Department of Surgical Oncology at Fox Chase Cancer Center, focusing on breast surgery. Dr. Aggon comes to Fox Chase from Crozer-Keystone Health System-Delaware County, where she has practiced as a breast surgeon and served as Medical Director of the Center for...
Stacey Ann Carter, MD, has joined the Lester and Sue Smith Breast Center, part of the National Cancer Institute–designated Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine and the Department of Surgery as Assistant Professor. Dr. Carter joins the Breast Center team as a...
A new study1 showing that just 1 in 20 terminally ill patients with cancer has sufficient understanding about the prognosis or purpose of treatment is highlighting the need for improvements in both the way oncologists communicate prognosis with their patients and in the development of educational...
Music therapy, an established adjuvant to standard cancer care, is offered in a growing number of cancer centers throughout the United States and internationally. Defined by the American Music Therapy Association (AMTA) as “the evidence-based use of music interventions to accomplish individual...
The American Association for Cancer Research (AACR) and its Chief Executive Officer, Margaret Foti, PhD, MD (hc), were honored with the PHL Life Sciences Ultimate Solution Award for their significant contributions to and impact on the field of cancer research. The award is presented annually by PHL ...
A recent study1 published in the Journal of Clinical Oncology (see “Breaking the ‘Conspiracy of Silence’” in this issue of The ASCO Post) found that just 1 in 20 patients with advanced, incurable cancer has sufficient understanding of his or her prognosis or life expectancy. Now, another new study ...
Cervical cancer incidence and mortality rates—perhaps more than any other chronic disease—shine a grim spotlight on global disparities of care. It is one of the most preventable of human malignancies, yet it is the leading cause of cancer deaths in women around the world. It kills 260,000 women...
The U.S. Food and Drug Administration (FDA) announced on September 15 that it has taken action against 55 tobacco retailers by issuing the first warning letters for selling newly regulated tobacco products—such as e-cigarettes, e-liquids, and cigars—to minors. These actions come about a month after ...
With the expansion of our understanding of signaling pathways in normal cells and how they are co-opted or corrupted in malignancy, the number of potential antitumor agents to be tested has exploded, exposing the limitations of traditional antineoplastic drug development and challenging us to...
A new study from Drexel University College of Medicine suggests all organ transplant recipients, regardless of race, should receive routine, total-body screenings for skin cancer. Out of 259 nonwhite transplant recipients who were evaluated in the study, 19 skin cancer lesions were identified in...
Research from Rutgers Cancer Institute of New Jersey and and other U.S. health and academic institutions shows a diet high in calcium and low in lactose may reduce the risk of ovarian cancer in African American women. The work, published by Qin et al in the British Journal of Cancer, also found sun ...
Maha H. Hussain, MD, has joined the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as the Associate Director for Clinical Sciences Research. Dr. Hussain will also serve as Co-Director of the Lurie Cancer Center’s Genitourinary Oncology Program, along with Edward Schaeffer,...
Julie E. Bauman, MD, MPH, a head and neck cancer specialist and physician-scientist, has been named Professor of Medicine and the new Chief of the Division of Hematology and Oncology at the University of Arizona (UA) College of Medicine–Tucson, as well as Associate Director of Translational...
Earlier this month, ASCO, in collaboration with the American Society for Radiation Oncology (ASTRO) and the Society for Surgical Oncology (SSO), jointly issued an update to a clinical practice guideline for physicians treating women with breast cancer who have undergone a mastectomy. The update...
The Basser Center for BRCA at Penn’s Abramson Cancer Center has announced the recipient of the 2016 Basser Global Prize is cancer geneticist Steven Narod, MD, FRCPC, PhD (hon), FRSC, Director of the Familial Breast Cancer Research Unit and a senior scientist at the Women’s College Hospital in...
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the first-line treatment of patients with advanced non–small cell lung cancer...
Clinicians face a number of questions in evaluating and treating patients with stage IIIA non–small cell lung cancer (NSCLC). One expert in the field, Rafael Santana-Davila, MD, reviewed key issues in managing this disease in the Journal of Oncology Practice (JOP). The ASCO Post asked Dr....
As reviewed in this issue of The ASCO Post, the U.S. Preventive Services Task Force (USPSTF) recently updated its guidelines for colorectal cancer screening1 from 2008 and has now included seven acceptable strategies, including direct-visualization modalities (ie, endoscopy and computed tomography...
The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for the use of ofatumumab (Arzerra) in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). The application, which...
The American Society of Hematology (ASH) will present the 2016 William Dameshek Prize to Charles Mullighan, MBBS (Hons), MD, of St. Jude Children’s Research Hospital, for his leadership in defining the landscape of genetic alterations of acute lymphocytic leukemia (ALL), which has provided...
Attendees at the 2016 Pan Pacific Lymphoma Conference held July 18–22 in Koloa, Hawaii, got a peek at early data for a number of novel agents in the treatment of various lymphoma subtypes. The ASCO Post captured these findings. Denintuzumab Mafodotin in Diffuse Large B-Cell Lymphoma Denintuzumab...
A small device implanted under the skin may improve breast cancer survival by catching cancer cells, slowing the development of metastatic tumors in other organs, and allowing time to intervene with surgery or other therapies. These findings, reported by Rao et al in Cancer Research, suggest a path ...
As reported in the Journal of Clinical Oncology, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, and colleagues have provided a summary of the groundwork of an initiative by ASCO and the Association of American Cancer Institutes (AACI) to identify and reduce...
For the majority of patients who are diagnosed with advanced-stage non–small cell lung cancer (NSCLC), platinum-based doublets have been the standard of care for over 30 years. Recently, the immune checkpoint inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) demonstrated superior survival ...
Although targeted drugs like imatinib (Gleevec) have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time. New research conducted by scientists at Dana-Farber Cancer Institute...
A new study indicates that adolescent females with acute leukemia have low rates of pregnancy screening prior to receiving chemotherapy that can cause birth defects. These findings were published by Rao et al in Cancer. Although many chemotherapy drugs can cause birth defects, there are no...
Today, Vice President Joe Biden announced a series of new steps focused on increasing access to information about clinical trials and improving the efficiency of our clinical research system. These steps include making it easier for participants to find clinical trial opportunities as quickly as...
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug...
A drop in the number of cancer cells detected in a patient’s blood could be the best indicator yet as to whether treatment for prostate cancer is working. A new study, published by Lorente et al in European Urology, shows that a 30% decline in a patient’s numbers of circulating tumor...
The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non–small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to...
On September 13, 2016, the U.S. Food and Drug Administration (FDA) modified the dosage regimen for nivolumab (Opdivo) for the currently approved indications for renal cell carcinoma, metastatic melanoma, and non–small cell lung cancer (NSCLC). The currently approved recommended dosage...
A first-of-its-kind joint report from the American Cancer Society and Alliance for Childhood Cancer has compiled the latest information related to pediatric cancer, including statistics and trends; a current list of drugs used to treat pediatric cancers; ongoing pediatric cancer clinical trials;...
An animal study suggests that resistance to tamoxifen therapy in some estrogen receptor–positive breast cancers may originate from in utero exposure to endocrine-disrupting chemicals. The study provides a new path forward in human research, as about half of the breast cancers treated with...
The Chinese Journal of Cancer (CJC) is soliciting the 150 most important questions in cancer research and clinical oncology from cancer researchers around the world. The editors of CJC believe this will help provide important insights and guidance in future efforts to advance cancer research...
Among individuals with advanced cancer, frequent hospitalization is often at odds with patient preference and is increasingly viewed as a hallmark of poor quality care. Hospitalization contributes substantially to costs and regional spending variation in this population, but patterns and reasons...
Radiation oncologists are frequently involved in providing palliative and supportive care for patients with advanced cancers through delivery of palliative radiation. Whether they are confident in their ability to assess and initiate treatments for pain, nonpain, and psychosocial distress is...
In 1997, Oregon enacted a voter initiative allowing terminally ill residents to self-administer physician-prescribed medication to end their lives called the Oregon Death With Dignity Act (ORDWDA). Statute requires prescriptions written for lethal medications be reported; the state also collects...
During hematopoietic stem cell transplantation (HSCT), patients sometimes experience physical and psychological symptoms that negatively impact their quality of life. Researchers led by Areej El-Jawahri, MD, Instructor of Medicine at Harvard Medical School, Director of the Bone Marrow Transplant...
There are limited data on the illness understanding and perception of curability among patients with advanced cancer receiving palliative care around the world. In a study led by Sriram Yennu, MD, MS, Associate Professor in the Department of Palliative Care and Rehabilitation Medicine at The...
A large observational study examining the variation in breast density assessment among radiologists in clinical practice has found a wide variation—from 6.3% to 84.5%—in the percentage of mammograms rated as showing dense breasts, which persisted after adjusting for patient characteristics. The...
Randy L. Wei, MD, PhD, of the University of California, Irvine, discusses findings from a survey that focused on ASTRO members who assessed their ability to deliver palliative and supportive care, and their access to continuing medical education on the topic (Abstract 105).
Sriram Yennu, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a study of an international cohort of patients with advanced cancer who received palliative care. Nearly half the patients incorrectly believed their cancer was curable (Abstract 5).
Stephen T. Sonis, DMD, DMSc, of Dana-Farber Cancer Institute, discusses the epidemiology, pathogenesis, and scope of oral complications of radiation therapy.
Jennifer S. Temel, MD, of Massachusetts General Hospital, discusses increasing prognostic uncertainty in light of targeted treatments and immunotherapies, and the difficulty predicting who will benefit.
Scott A. Irwin, MD, PhD, of Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses delirium—its definition, prevalence, consequences, assessment, and management.
Eric Roeland, MD, of the University of California, San Diego, discusses the key papers presented at this year’s Palliative Care in Oncology Symposium.
Emily Haozous, PhD, RN, of the University of New Mexico, discusses health disparities and cultural differences in palliative and end-of-life care, with case study examples drawn from American Indian communities.
Eileen Danaher Hacker, PhD, APN, AOCN, of the University of Illinois at Chicago, discusses study findings that show improvement in physical activity, fatigue, muscle strength, and functional ability (Abstract 190).
Charles F. von Gunten, MD, PhD, of OhioHealth, discusses hospice care as a measure of quality, and findings that show medical oncologists doubled the median length of hospice service from 20 days to 40 days (Abstract 45).